Merck stock holds firm after Keytruda trial momentum
Published on 08/27/2026 at 18:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (US58933Y1055) opened at $153.21 on August 27, 2026, with a market cap of $378.00 billion and a second-quarter revenue print of $16.61 billion from August 4, 2026. The same report showed adjusted EPS of $0.13 loss, while consensus had called for a $0.26 loss, a $0.13 beat on the bottom line.
Earnings still frame the tape
The August 4, 2026 earnings release also showed revenue up 5.1% year over year from the prior-year quarter and net margin of 4.77%, giving investors a cleaner read on how the current business mix is working. FY 2026 guidance stands at $2.66 to $2.76 in EPS, which puts the latest quarter in a broader full-year context.
That combination matters because the stock is still trading with a high absolute valuation, even after the recent move, and the gap between reported EPS and the prior-year $2.13 print shows how sharply the comparison base has changed.
Trial news adds a second layer
Recent reporting tied Merck to positive Phase 3 melanoma data for its personalized mRNA cancer vaccine with Moderna, a result that also helped move the share price in the latest session. The market reaction lifted the stock to $152.85 in one report, which put it within striking distance of the 52-week high at $154.49.
For investors, the key point is that the stock is being priced on both pipeline optionality and the existing earnings base. The first supports the story; the second keeps the numbers grounded.
Keytruda remains central
Keytruda is still the company’s best-known product and the anchor for Merck's oncology franchise, so any vaccine-related progress is read through that lens. The franchise matters because it links new pipeline data to an already scaled commercial base.
Merck stock near recent highs
Merck stock traded at $153.21 on August 27, 2026, and another market snapshot put the share price at $151.79 with a year-to-date gain of 0.58%. The stock's 52-week band and the $378.00 billion market cap show how much of the move has already been absorbed into valuation.
Company
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: NYSE
Sector / Industry: Health Care / Pharmaceuticals
Index membership: Dow Jones Industrial Average
